Checchi Capital Advisers LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 31,434 shares of the company’s stock after selling 1,061 shares during the quarter. Johnson & Johnson makes up 0.5% of Checchi Capital Advisers LLC’s investment portfolio, making the stock its 18th largest position. Checchi Capital Advisers LLC’s holdings in Johnson & Johnson were worth $4,067,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of JNJ. Virtus ETF Advisers LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $25,000. Krane Funds Advisors LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $26,000. Financial Advantage Inc. bought a new position in Johnson & Johnson in the 3rd quarter worth about $28,000. Crewe Advisors LLC boosted its stake in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares during the period. Finally, Eii Capital Management Inc. bought a new position in Johnson & Johnson in the 3rd quarter worth about $39,000. Institutional investors own 72.21% of the company’s stock.
JNJ has been the subject of several analyst reports. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price for the company in a research note on Thursday, October 17th. Credit Suisse Group raised their target price on Johnson & Johnson from $158.00 to $163.00 in a research note on Thursday, October 24th. Raymond James cut their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $151.64.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the company posted $2.05 EPS. As a group, analysts predict that Johnson & Johnson will post 8.66 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.82%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Trading based on a resistance level
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.